New drug duo shows promise for advanced colorectal cancer patients who can't tolerate chemo
NCT ID NCT07398326
First seen Feb 11, 2026 · Last updated May 23, 2026 · Updated 18 times
Summary
This study tests a combination of two approved drugs, anlotinib and sintilimab, as a first treatment for people with advanced colorectal cancer that has spread but not to the liver. The goal is to shrink or control the cancer while avoiding standard chemotherapy. The trial enrolls 37 adults who cannot or choose not to receive chemo, and will measure how well the tumors respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital of Naval Medical University
RECRUITINGShanghai, 200003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.